Artelo Biosciences Inc ARTL:NASDAQ

Last Price$0.31NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change-0.007(2.15%)
Bid (Size)$0.30 (61)
Ask (Size)$0.32 (2)
Day Low / High$0.30 - 0.32
Volume205.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022


Artelo Biosciences Inc ( NASDAQ )

Price: $0.31
Change: -0.007 (2.15%)
Volume: 205.4 K
4:00PM ET 7/01/2022

LogicBio Therapeutics Inc ( NASDAQ )

Price: $0.40
Change: +0.05 (13.16%)
Volume: 303.8 K
4:00PM ET 7/01/2022

Hoth Therapeutics Inc ( NASDAQ )

Price: $0.42
Change: -0.004 (1.00%)
Volume: 259.3 K
4:00PM ET 7/01/2022

Neurobo Pharmaceuticals Inc ( NASDAQ )

Price: $0.47
Change: -0.01 (2.04%)
Volume: 39.2 K
3:49PM ET 7/01/2022

Statera Biopharma Inc ( NASDAQ )

Price: $0.28
Change: -0.009 (3.33%)
Volume: 490.0 K
4:00PM ET 7/01/2022

Read more news Recent News

Artelo Says ART27.13 Shows Positive Pre-Clinical Results in Protecting Muscles From Cancer-Linked Degeneration; Shares Surge
9:32AM ET 4/13/2022 MT Newswires

Artelo Biosciences (ARTL) said Wednesday its candidate drug ART27.13 showed "promising pre-clinical results" in protecting human muscle cells from...

Artelo Biosciences, Trinity College Dublin Agree to Expand Partnership
10:53AM ET 3/28/2022 MT Newswires

Artelo Biosciences (ARTL) said Monday it agreed to expand its partnership with Trinity College Dublin with a focus on investigating the cellular biology of...

Artelo Biosciences Receives Patent Covering Means for Treating Medical Conditions Using Cannabidiol Cocrystal Composition
10:34AM ET 3/02/2022 MT Newswires

Artelo Biosciences (ARTL) said Wednesday the US Patent and Trademark Office issued a notice of allowance for a patent application pertaining to ART12.11, a...

Artelo Biosciences' Lead Cannabinoid No Longer Schedule 1 Controlled Substance in UK; Shares Rise Pre-Bell
9:30AM ET 1/11/2022 MT Newswires

Artelo Biosciences (ARTL) reported that the UK government no longer considers the company's lead clinical cannabinoid ART27.13 a Schedule 1 controlled...

Company Profile

Business DescriptionArtelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded by James Manley on May 2, 2011 and is headquartered in Solana Beach, CA. View company web site for more details
Address505 Lomas Santa Fe
Solana Beach, California 92075
Number of Employees2
Recent SEC Filing06/27/20224
President, CEO, CFO, Secretary & TreasurerGregory D. Gorgas
Vice President-Finance & OperationsRandy Schreckhise
Chief Medical OfficerSteven D. Reich
Chief Scientific Officer & Senior Vice PresidentAndy Yates

Company Highlights

Price Open$0.32
Previous Close$0.32
52 Week Range$0.28 - 1.32
Market Capitalization$13.1 M
Shares Outstanding42.3 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings AnnouncementN/A

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.33
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-50.91%

Analyst Ratings as of 05/12/2022

Consensus RecommendationConsensus Icon
Powered by Factset